Concert Pharmaceuticals files to go public in $75M offering

A Lexington company that aims to improve upon approved or nearly-approved drugs by making them more molecularly stable, Concert Pharmaceuticals is the fourth biotech in the past month to file plans to go public...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.